Drugs: vepdegestrant, Veppanu
FDA approves Vepdegestrant (Veppanu) for ESR1-mutated breast cancer
250% citation coverage2 regulatory sources
Intelligence Snapshot
Executive Summary
The FDA approved vepdegestrant (Veppanu) on May 1, 2026 for a biomarker-selected population: adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy.
Key Insights
-
Veppanu is an oral heterobifunctional protein degrader, manufactured by Arvinas…
Veppanu is an oral heterobifunctional protein degrader, manufactured by Arvinas Operations, Inc.
-
In a study, people who took vepdegestrant lived longer without the cancer growing than…
In a study, people who took vepdegestrant lived longer without the cancer growing than people on Faslodex, supporting the regulatory approval in the post-endocrine setting.
-
Track ongoing trials, label updates, and additional clinical publications as the…
Track ongoing trials, label updates, and additional clinical publications as the regulatory and clinical narrative develops.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
The FDA approved vepdegestrant (Veppanu) on May 1, 2026 for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy. For BD teams and investors, the key read-through is a new catalyst tied to an FDA-labeled oral protein degrader and a clearly defined biomarker-selected population.
Loading intelligence…
Loading intelligence…
Quick Answer
Key Questions
- What changed with the Vepdegestrant FDA approval?
- Who is eligible for Veppanu treatment?
- What is the mechanism of action of Vepdegestrant?
- What clinical evidence supports the Veppanu approval?
- Where can I find the Veppanu package insert and FDA label?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for vepdegestrant.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Contents13 sections
FDA Approves Vepdegestrant (Veppanu) for ESR1-Mutated Breast Cancer
FDA approval defines a new biomarker-selected option
The U.S. Food and Drug Administration approved vepdegestrant (brand name: Veppanu) on May 1, 2026, establishing a labeled oral option for a molecularly defined subset of hormone receptor-positive breast cancer. According to the FDA label, Veppanu is indicated for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. This precision-medicine framing ties the indication directly to biomarker detection, a regulatory move that clarifies the clinical boundaries for prescribing and trial enrollment.
IntelligenceRegulatory Impact
FDA decisions frame this story. Regulatory relevance is high for estrogen receptor-positive, HER2-negative breast cancer, with vepdegestrant and Veppanu most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
The FDA label frames Veppanu as an oral heterobifunctional protein degrader
Veppanu is a heterobifunctional protein degrader, administered orally. The drug is manufactured by Arvinas Operations, Inc. The Veppanu package insert will provide detailed dosing, safety, and pharmacology information. Clinicians and compliance teams should reference the official FDA prescribing information for the Vepdegestrant FDA label.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high for estrogen receptor-positive, HER2-negative breast cancer. Expect implications for pricing, access, and launch sequencing.
Clinical context supports the approval
In a study, people who took vepdegestrant lived longer without the cancer growing than people on Faslodex, establishing a clinical rationale for the approval in the post-endocrine setting.
IntelligenceStrategic Takeaways
The FDA approved vepdegestrant (Veppanu) on May 1, 2026 for a biomarker-selected population: adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy. Veppanu is an oral heterobifunctional protein degrader, manufactured by Arvinas Operations, Inc. In a study, people who took vepdegestrant lived longer without the cancer growing than people on Faslodex, supporti
What to watch next in the vepdegestrant story
Several trials remain active or recruiting. ClinicalTrials.gov NCT05654623 is a Phase 3 study of vepdegestrant in advanced metastatic breast cancer, currently active but not recruiting. NCT06125522 (TACTIVE-U), a Phase 1/2 study of vepdegestrant in combination with other medicines, is active but not recruiting, and NCT04606446, a Phase 2 study of vepdegestrant in ER-positive, HER2-negative breast cancer and other solid tumors, is recruiting.
Watch for publication of the Veppanu package insert and the full Vepdegestrant FDA label. Track trial readouts and additional clinical publications as the regulatory and clinical narrative develops.
IntelligenceEvidence Quality
Grounded in 2 regulatory sources.
Key Takeaways
- The FDA approved vepdegestrant (Veppanu) on May 1, 2026 for a biomarker-selected population: adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy.
- Veppanu is an oral heterobifunctional protein degrader, manufactured by Arvinas Operations, Inc.
- In a study, people who took vepdegestrant lived longer without the cancer growing than people on Faslodex, supporting the regulatory approval in the post-endocrine setting.
- Track ongoing trials, label updates, and additional clinical publications as the regulatory and clinical narrative develops.
Drug Snapshot
| Drug | vepdegestrant |
|---|---|
| Generic name | VEPDEGESTRANT |
| Manufacturer | Arvinas Operations, Inc. |
| Route | ORAL |
| Indication | 1 INDICATIONS AND USAGE VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. VEPPANU is a heterobifunctional protein degrader indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1) -mutated advanced or metastatic |
Regulatory Summary
- Approved indication: 1 INDICATIONS AND USAGE VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. VEPPANU is a heterobifunctional protein degrader indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1) -mutated advanced or metastatic
- Arvinas Operations, Inc. develops vepdegestrant
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT06125522 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | Pfizer |
| NCT04606446 | Study of PF-07248144 in Advanced or Metastatic Solid Tumors | RECRUITING | PHASE2 | Pfizer |
| NCT04072952 | A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer | COMPLETED | PHASE1, PHASE2 | Arvinas Estrogen Receptor, Inc. |
| NCT07231991 | A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function | RECRUITING | PHASE1 | Pfizer |
| NCT05654623 | A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 | Pfizer |
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| Novartis Pharmaceuticals | estrogen receptor-positive, HER2-negative breast cancer | 2 |
| Alliance for Clinical Trials in Oncology | estrogen receptor-positive, HER2-negative breast cancer | 2 |
| University Health Network, Toronto | estrogen receptor-positive, HER2-negative breast cancer | 1 |
| National Cancer Institute (NCI) | estrogen receptor-positive, HER2-negative breast cancer | 1 |
| Hoffmann-La Roche | estrogen receptor-positive, HER2-negative breast cancer | 1 |
| Mayo Clinic | estrogen receptor-positive, HER2-negative breast cancer | 1 |
Timeline
- Active_Not_Recruiting trial NCT06125522 (PHASE1, PHASE2)
- Recruiting trial NCT04606446 (PHASE2)
- Recruiting trial NCT07231991 (PHASE1)
- Active_Not_Recruiting trial NCT05654623 (PHASE3)
Frequently Asked Questions
What changed with the Vepdegestrant FDA approval?
On May 1, 2026, the FDA approved vepdegestrant (Veppanu) for a specific patient population: adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after prior endocrine therapy.
Who is eligible for Veppanu treatment?
Veppanu is indicated for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Biomarker testing is a regulatory requirement for patient identification.
What is the mechanism of action of Vepdegestrant?
Veppanu is a heterobifunctional protein degrader. The FDA label describes the drug class; clinicians and researchers should consult published literature and the full prescribing information for additional mechanistic details.
What clinical evidence supports the Veppanu approval?
In a study, people who took vepdegestrant lived longer without the cancer growing than people on Faslodex. Full trial data should be reviewed in published manuscripts and regulatory submissions.
Where can I find the Veppanu package insert and FDA label?
The FDA label for Veppanu is available through the FDA. Healthcare providers and patients should consult the official prescribing information for dosing, contraindications, warnings, and adverse reactions.
What trials are ongoing for vepdegestrant?
Several trials are active or recruiting. NCT05654623 is a Phase 3 trial of vepdegestrant in advanced metastatic breast cancer, currently active but not recruiting. NCT06125522 (TACTIVE-U) is a Phase 1/2 combination study, active but not recruiting, and NCT04606446 is a Phase 2 trial recruiting patients with ER-positive, HER2-negative breast cancer and other solid tumors.
Related profiles
Continue Exploring
Jump into the entities behind this story.
Ask AI About estrogen receptor-positive, HER2-negative breast cancer
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow vepdegestrant developments
FDA estrogen receptor-positive, her2-negative breast cancer alerts and vepdegestrant pipeline updates, every Monday.
- Sources analyzed
- 1
- Evidence strength
- 100/100
- Last verified
- Jun 11, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
